Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy

BACKGROUND: With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, drug–drug interactions (DDIs) emerged as significant challenge. Since then, HCV therapy and the infected population have rapidly changed. So far, very limited data are available regarding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulte, Benjamin, Wübbolding, Maximilian, Marra, Fiona, Port, Kerstin, Manns, Michael P, Back, David, Cornberg, Markus, Stichtenoth, Dirk O, Höner zu Siederdissen, Christoph, Maasoumy, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033915/
https://www.ncbi.nlm.nih.gov/pubmed/32104719
http://dx.doi.org/10.1093/ofid/ofaa040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033915/
https://www.ncbi.nlm.nih.gov/pubmed/32104719
http://dx.doi.org/10.1093/ofid/ofaa040

Ejemplares similares